Trials / Completed
CompletedNCT00796757
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma. Patients will receive Avastin (10mg/kg iv) every 2 weeks in combination with a low dose of interferon alfa-2a (3 MIU sc three times per week (t.i.w.). The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab [Avastin] | 10mg/kg iv infusion every 2 weeks |
| DRUG | interferon alfa-2a | 3 MIU sc t.i.w. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2008-11-24
- Last updated
- 2015-05-27
- Results posted
- 2015-05-27
Locations
50 sites across 12 countries: Czechia, Estonia, Finland, Germany, Greece, Italy, Lithuania, Netherlands, Russia, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00796757. Inclusion in this directory is not an endorsement.